Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Diabetic men have lowered overall prostate cancer (PCa) risk, while their risk of high-grade disease may be elevated. The antidiabetic drug metformin may reduce the risk. This study evaluated PCa incidence among users of metformin and other antidiabetic drugs in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). METHODS: The study population (78,615 men) was linked to the national prescription database. Hazard ratios (HRs) and 95% confidence intervals (CIs) for PCa were estimated using Cox regression, with medication use as a time-dependent variable. The effect of diabetes was estimated by comparing antidiabetic drug users to non-users, while drug-specific effects were evaluated within antidiabetic drug users. Analyses were performed in both study arms of FinRSPC. RESULTS: Compared to non-users, men using antidiabetic drugs had lowered overall PCa risk (HR 0.85, 95% CI 0.79-0.92), and this association was not affected by PCa screening. However, the risk of metastatic PCa was increased (HR 1.44, 95% CI 1.09-1.91). Among antidiabetic drug users, metformin decreased overall PCa risk (HR 0.81, 95% CI 0.69-0.95) in a dose-dependent manner. When stratified by FinRSPC study arm, the risk reduction was observed only in the screening arm. Sulphonylureas increased the risk of metastatic PCa (HR 2.04, 95% CI 1.11-3.77). Use of thiazoledenediones or insulin was not associated with PCa risk. CONCLUSION: Among antidiabetic drug users, metformin lowered the overall PCa risk, while the risk of metastatic disease was elevated in sulphonylurea users. As sulphonylureas stimulate insulin secretion, the results suggest that hyperinsulinemia may be a risk factor for PCa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metformin and prostate cancer mortality: A meta-analysis
Stopsack, K. H., Ziehr, D. R., Rider, J. R., & Giovannucci, E. L. (2016) · Cancer Causes & Control · doi:10.1007/s10552-015-0687-0 · Cited by 72 · cited 1×
“The anticancer properties of metformin are supported by epidemiological studies reporting lowered PCa mortality in metformin users [5].”
Background
Cited by
Epidemiology and Prevention of Prostate Cancer
Gandaglia, G., Leni, R., Bray, F., Fleshner, N., Freedland, S. J., Kibel, A., Stattin, P., Van Poppel, H., & La Vecchia, C. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.09.006 · Cited by 611
Mallik, R., & Chowdhury, T. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.023 · Cited by 260
Zhang, K., Bai, P., Dai, H., & Deng, Z. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2020.06.001 · Cited by 84
Murtola, T. J., Vihervuori, V. J., Lahtela, J., Talala, K., Taari, K., Tammela, T. L., & Auvinen, A. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0055-4 · Cited by 28
Self-citationMurtola, T. J., Sälli, S. M., Talala, K., Taari, K., Tammela, T. L. J., & Auvinen, A. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0123-0 · Cited by 13
Self-citation
Metadata
- Authors
- Haring, A., Murtola, T. J., Talala, K., Taari, K., Tammela, T. L. J., & Auvinen, A.
- Venue
- Scandinavian Journal of Urology
- Publisher
- Medical Journals Sweden AB
- Published
- 2017-01-02
- Volume
- 51
- Issue
- 1
- Pages
- 5-12
- ISSN
- 2168-1805 (ISSN-L)
- 2168-1813
- OpenAlex
- W2579153153
- Cited by
- 52
- References
- 1
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. https://app.cochat.ai/papers/10.1080/21681805.2016.1271353
- The paper
- Haring, A., Murtola, T. J., Talala, K., Taari, K., Tammela, T. L. J., & Auvinen, A. (2017). Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scandinavian Journal of Urology. https://doi.org/10.1080/21681805.2016.1271353
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.